Lansoprazole Intravenous 30 mg Specified Drug-use Survey [Hemostatic Effect/Rebleeding Rate]

NCT02151786 · clinicaltrials.gov ↗
COMPLETED
Status
1120
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Takeda